View this email in browser.

In multiple myeloma, outcomes are poor for refractory patients who are recycled on an anti-CD38 mAb¹

According to a prospective analysis of 32 patients refractory to an anti-CD38 mAb:

Recycling an anti-CD38 mAb–based regimen in the next line of therapy resulted in an ORR of 0%, mPFS of 1.6 months, and mOS of 10.7 months¹

The National Comprehensive Cancer Network^® (NCCN^®) suggests regimens without anti-CD38 be considered for patients refractory to anti-CD38 antibody as long as they have not received or are refractory to other agents in the regimen²

Consider an option that introduces a different treatment class for your patients relapsing on an anti-CD38 mAb–based regimen

LEARN MORE

Abbreviations: mAb, monoclonal antibody; mOS, median overall survival; mPFS, median progression-free survival; ORR, overall response rate.

NCCN, National Comprehensive Cancer Network.

References: 1. Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer. 2021;11(5):89. doi:10.1038/s1408-1408-021-00478-4 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Multiple Myeloma v2.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 9, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Colorado and Connecticut prescribers click here for Wholesale Acquisition Cost price disclosure pursuant to Colorado House Bill 19-1131 and Connecticut Public Act 23-171.

Vermont prescribers click here for Average Wholesale Price disclosure pursuant to Vermont law 18 V.S.A. § 4633.

To opt out of emails from Karyopharm Updates, please click here.

This content is sponsored by Karyopharm Therapeutics, and ION Oncology Practice Network has not independently reviewed or verified the information provided by Karyopharm Therapeutics.

This email was sent to madeleine.dillon@cencora.com because you have an account with or are a valued partner of ION Oncology Practice Network. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.